Home / Transcripts / Coherus Oncology, Inc. (CHRS) · August 5, 2026

Coherus Oncology, Inc. (CHRS) Earnings Call Transcript

August 5, 2026

NASDAQ US Health Care Biotechnology earnings 42 min

Earnings Call Speaker Segments

Carrie Graham executive
#1

Thanks, Heidi. Good afternoon, everyone, and welcome to the Coherus Oncology Second Quarter 2026 Earnings Conference Call. Here with me today to go over our results are Denny Lanfear, our Chief Executive Officer at Coherus; Dr. Rosh Dias, who serves as Chief Medical Officer; Dr. Theresa Lavallee, our Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer. Before we begin, please let me note that forward-looking statements about Coherus' current expectations regarding future events are part of today's call. Results could differ materially, and we have no obligation to update or revise any forward-looking statements. For additional details on risks and uncertainties, please refer to the press release we issued today as well as our quarterly report on Form 10-Q. I'll now hand the call over to Denny.

Dennis Lanfear executive
#2

Thanks, Carrie, and I appreciate everyone being with us this afternoon for the Q2 2026 quarterly call. As all of you are aware, we've entered an exciting stretch in which we're generating initial clinical data and seeing readouts, rather than reporting definitive data, and we want to share the insights currently available about how things are shaping up so far; before that, though, allow me to offer a few comments regarding the scientific emphasis on defeating immune resistance in cancer, so you'll have a lens for viewing our pipeline and how we're approaching development. When we look across the immuno-oncology drug data in cancer, we're reminded that the benefit from immunotherapy largely appears at the far tail of the survival curve, the place where it counts most for patients and for regulators alike. On top of that, combination agents are capable of making a substantial difference. Chemotherapy combined with PD-1s is a strong illustration: PD-1s transformed cancer care by tackling immune invasion, and they delivered some of the most striking survival gains when given alongside drugs that cause tumor cell death. It's crucial to remember that tagmokitug, being a Treg depleting agent, is positioned mechanistically not as yet another response rate agent in the manner of chemo or ADCs, but rather as a horizontally enabling durability layer that takes away the brake, Tregs, which may cap both how deep and how long responses last with a range of active agents; that maps directly onto our tagmokitug development program, which, first of all, offers a rational scientific framework for assessing Treg depletion across multiple cancers and different lines of therapy in terms of response and duration. Second, it has been deliberately built to yield insights into where Treg depletion fits best, with which combinations and in which lines of therapy, and to pinpoint the best patients for long-term survival benefit, which is the key approval criterion; and, importantly, to clarify how Treg depletion relates to immune context, T cells and other factors required for efficacy. Grasping how biomarkers and immune context factors connect to response duration demands a robust biomarker program for context and to set the direction for future development. That program is in place, and we're currently analyzing these data. Our immune resistance emphasis on survival and duration of clinical benefit also carries over to the casdozokitug program and the ongoing first-line HCC study combining it with toripalimab, and bevacizumab, which builds on the earlier casdozokitug study that showed improved survival and strong complete response data. But it's worth noting that both the duration and the depth of response took several months. Once again, we have the right biomarker program in place and are analyzing these data now that the CADILYZE study is fully enrolled; we gave you a preview of this on our previous call. And today, during this call, Dr. Lavallee, our Chief Scientific and Development Officer, will take things further and talk with you about TIRI, our tumor immune regulatory index, in the context of our Tagmokitug studies. Next up after Theresa is our Chief Commercial Officer, Sameer Goregaoker, and he'll walk through how LOQTORZI is performing. Then Bryan McMichael, who serves as our Chief Financial Officer, will share some detail regarding operational results for the quarter along with cash and the balance sheet. Before any of that, though, I want to pass the floor to Dr. Dias, our Chief Medical Officer, so he can brief everyone on fresh data coming out of the clinical studies. Rosh?

Rosh Dias executive
#3

Thanks, Denny. I'm happy to share that full enrollment has been reached in 3 of our studies, and I can offer a few early observations on the data sets starting to emerge. Beyond our CADILYZE trial in first-line HCC, which was already fully enrolled, our TAGMO cohorts in head and neck squamous cell as well as colorectal cancer have now likewise reached full enrollment. That said, patient accrual is still ongoing in other cohorts. It's worth bearing this in mind, because as we get closer to the first data readouts from our clinical program, two factors will chiefly govern when data arrive: how many patients are in a study, and how many scans may be needed to give a meaningful signal of activity. Alongside telling us about response, an adequate scan count yields useful insight into how long activity lasts, for both response and stable disease. That matters especially given that a great deal of the benefit seen with IO has come from extending the tail of the curve — in other words, the durability of activity. We currently have 2 active protocols plus one slated to begin within the next few months, and let me go through each pipeline program in turn, beginning with the TREGCHECK program for tagmokitug, our highly selective CCR8 cytolytic antibody. Our first protocol examines TAGMO in head and neck squamous cell carcinoma; it's a 40-patient study looking at 2 doses of TAGMO combined with TORI in a second-line head and neck squamous cell population, posing the very specific question of whether PD-1 resistance can be reversed in that second-line population. As I said, I'm happy to report full enrollment here. This study rests on prior data we shared at AACR last year, in which, at earlier stages of this same study, we showed clear tumor remodeling with TAGMO monotherapy plus a partial response in a fourth-line patient with HPV-positive head and neck squamous cells among 7 patients given TAGMO and TORI together. Formal data cleaning has yet to be triggered in the ongoing study because too few patients have reached data maturity, but based on emerging data from a subset of patients I can offer these high-level comments. First, so far the TAGMO plus TORI combination has displayed a safety profile that is acceptable and manageable. Second, we've observed evidence that adding TAGMO to TORI for treating PD-1 resistance in the second-line head and neck population has demonstrated activity when it comes to response rate and treatment duration. Specifically, in our analyses of baseline tumor samples, preliminary data from the early batches of samples suggest there may be an immune context that enriches for patient benefit. Given the limited number of cases in our dataset among the subgroup of individuals for whom biomarker results could be paired, what we are observing is more pronounced activity among those testing positive for HPV — a setting in which a substantial unmet medical need persists — as well as among those whose tumor immune regulatory index, or TIRI, score is elevated, something Theresa will cover in more detail shortly. One important qualification applies: these early findings rest on information that is not yet fully mature and, crucially, has not yet undergone formal cleaning, so changes remain possible. Should such patterns hold as the information matures further, that could lend support to an <<inaudible>> approach in head and neck squamous cell carcinoma. I expect the information to mature further across the next several months, encompassing examination of the biomarker samples still outstanding, and present projections suggest we will probably have every patient with enough follow-up and biomarker analysis completed to permit a formal disclosure in October. Turning to protocol number two, which examines TAGMO across a chosen set of GI cancers. Cohort A covers a second-line upper GI adeno group — gastric adenocarcinoma, esophageal adenocarcinoma and GEJ cancers — enrolling 40 patients, once more receiving 2 doses of TAGMO alongside TORI. Although accrual is close to finishing, it is not yet complete, so it remains too early to offer any further detailed remarks about this cohort. As for our projections, we expect the entire group of patients to have undergone a sufficient number of scans within the next few months, and as a result we presently expect to be able to report data later this year. Cohorts B and C are examining the TAGMO-TORI pairing in second-line and first-line esophageal squamous cell carcinoma, respectively. Both cohorts remain open to enrollment. The second-line group involves 20 patients receiving the doublet, while the first-line group adds chemo to that doublet as a safety cohort of 12 patients. Up to this point, the safety profile has looked acceptable and manageable. Cohort D studies TAGMO plus TORI in colorectal carcinoma, with 20 patients in the fourth-line plus MSS group, initially focused on non-liver mets, with plans to expand to a possible further 21 patients as well as a liver mets group. I am delighted to report that although this was the final cohort to open, accrual of the first 20 patients is now complete — a clear acknowledgment of the unmet medical need in colorectal carcinoma. Present projections suggest all 20 patients ought to have undergone enough scans within the next couple of months, so we still expect initial data to become available later this year. Lastly, protocol number three, built to allow TAGMO combinations with novel agents, stays on schedule to begin during the fall period, starting with its first cohort pairing TAGMO with Pasritamig, J&J's T-cell engager, in metastatic castrate-resistant prostate cancer. I'll wrap up by discussing Casdozo in hepatocellular carcinoma. This trial involves 72 patients and looks at combining Casdozo, TORI, and bev in the first-line HCC setting, with three goals in mind: generating data that backs up the contribution of each component along with Project Optimus, and naturally, better defining both efficacy and safety. To remind everyone, this rests on the promising findings from the earlier trial in which Casdozo was combined with the existing standard regimen of atezo plus bev. Even though accrual wrapped up in March, right now just about 50% of those patients have undergone 3 scans. So we still haven't hit a level of data maturity that would justify launching a formal analysis. On top of that, collection and analysis of ctDNA together with baseline IL-27 levels remains underway. Given all this, we expect the first data to become available in Q4 of this year; with that, I'll hand things over to Theresa. Theresa?

Theresa Lavallee executive
#4

Thanks, Rosh. Good afternoon, everyone. I'd like to build on what Rosh said regarding the TREGCHECK study. From an early data set we have available, looking at a subset of patients who have head and neck squamous cell carcinoma and whose disease is resistant to a PD-1 inhibitor, TAGMO was shown to bring back the anticancer activity of that PD-1 inhibitor. That signal might be stronger when the tumor immune regulatory index, or TIRI score, is picked up. We've characterized our TREGCHECK clinical development program as deliberate, built to identify the optimal immune context in which patients stand to gain from Tagmokitug treatment. Why does this matter to us? Since it has been shown to play a part in why the PD-1 drugs work. It's widely recognized that tumor PD-L1 expression may be necessary to enrich for those patients likely to gain from antibodies targeting PD-1 and PD-L1. The reason is that it sets the immune context for the point at which therapy can reactivate the immune response within the tumor. The degree of PD-L1 expression needed before treatment differs by tumor type, ranging from a score above 1, 10, 20, 50, and it also differs depending on whether the regimen is given alone or in combination. Pinpointing a TIRI score as a tumor immune regulatory index that enriches for patients in the PD-1 resistant space to be treated with tagmokitug and toripalimab could prove informative. It's gratifying to note that we are seeing a higher TIRI score among HPV-positive tumors. And in an interim analysis covering a subset of patients, we are observing a better clinical benefit rate in head and neck cancer patients whose tumors are HPV positive; we must emphasize that these data are early and, beyond the fact that the numbers so far are small, this analysis is retrospective as well. Still, since it ties to the target CCR8-positive Tregs, we feel encouraged and are concentrated on extending these findings as we think through development strategies. HPV-positive head and neck cancer in particular represents a high unmet medical need, given its rising incidence and the limited options for treatment. The question we will now investigate is whether that same TIRI score will enrich for clinical benefit in other tumor types, or in the first-line setting, with or without chemotherapy. As I've just described, one focus of our clinical development program is assessing immune context and opportunities for biomarker enrichment. A second goal is to explore which combinations are tolerated and meaningfully boost activity alongside tagmokitug. We keep demonstrating that tagmokitug and toripalimab are tolerated. In the months ahead, we will report on the full chemotherapy cohort and, on top of that, broaden to a new combination when we launch the study with Pasritamig, a T-cell engager. Now, returning to head and neck cancer. We're mindful of the treatment landscape evolving quickly and of the expected shift in standard of care. With the EGFR bispecifics and ADCs, we've observed striking overall response rates. However, they bring a notable amount of toxicity, and certain ones require dosing more often than IgG-based monoclonal antibodies do. A portion of these treatments might produce short-lived responses that fail to generate meaningful overall survival. It's worth highlighting that responses to immunotherapy differ in clear ways from those to targeted therapy. Immunotherapy frequently yields a reduced overall response, which is what the KEYNOTE-048 Phase III trial of pembrolizumab in head and neck cancer demonstrated, yet it provides lasting clinical benefit and lifts that tail on the survival curve. Among the 3 arms in KEYNOTE-048, the pembrolizumab monotherapy arm showed the smallest overall response rate, yet it possessed a robust tail that produced an OS benefit supporting approval. Regarding TAGMO-KEYTRDA, our attention is on the tolerability profile, the dosing schedule, and the capacity to provide durable benefit. I'll now hand things over to Sameer, our Chief Commercial Officer.

Sameer Goregaoker executive
#5

Thanks, Theresa. We're happy with how we executed commercially during Q2, since we keep seizing the chance to make LOQTORZI the leader in NPC. Two strong drivers power this brand: convincing 6-year data showing better efficacy, plus preferred NCCN guidelines that cement LOQTORZI as an obvious treatment option for NPC patients. Net sales for Q2 came in at $13.6 million, which is 15% growth versus the prior quarter. Notably, demand bounced back into the 10% to 15% range quarter over quarter after the seasonal dip seen earlier this year. We also posted, during this quarter, our largest number of new patient starts since the launch. Meanwhile, discontinuations among patients went back to longer-term historical norms after the temporary rise seen in Q1. Duration of therapy, too, keeps showing gradual gains. All these trends combined signal a healthy, durable revenue base, which gives us confidence about hitting our long-term projections. Looking forward, considerable runway lies ahead. Our broadened claims analysis reveals a meaningful chance to cut inferior chemotherapy alone further, especially within the community setting. Beyond that, we stay focused on displacing off-label IOUs and on backing proper treatment duration for existing patients. To seize these chances, we've kept investing in capabilities letting us spot, educate, and engage the right physician at the right moment through physician-level claims data. Education around the 6-year long-term survival data remains central to each customer interaction. Recent advisory boards affirmed that such data is highly motivating and can push meaningful change in physician behavior. Also, a novel pilot program with a leading HCP AI platform is now running, which further supports timely physician education. Going forward, we anticipate average quarterly growth within the 10% to 15% range, backed by wider adoption across segments. Crucially, our experience indicates that once a physician builds familiarity with LOQTORZI, usage grows deeper over time, thereby strengthening how durable our growth opportunity is; to sum up, we finished the quarter with fresh momentum and solid execution; we stay confident LOQTORZI is positioned well to reach a $15 million quarter in 2026, a $30 million quarter in 2027, and a peak market share quarter by 2028, in line with our earlier projections. With that, I'll hand the call over now to Bryan McMichael, our Chief Financial Officer.

Bryan McMichael executive
#6

Thank you, Sameer. The second quarter of 2026 represented one year since we sold off the UDENYCA franchise, a move that let us cut our secured and convertible debt by more than 90%, shrink our overall cost structure, and bring down our core cash burn as we repositioned the company. Those advantages have been both favorable and meaningful. Research and development from continuing operations came to $21.4 million in Q2 '26, compared with $26.3 million during the same quarter a year earlier. That drop stemmed mainly from savings tied to fewer employees along with reduced clinical trial and R&D manufacturing expenses. SG&A expense from continuing operations totaled $21.0 million in the second quarter, versus $26.0 million in Q2 2025. This decline largely reflected savings from a smaller workforce and lower operating costs after leaving the biosimilar business. Q2 stretches our run to 6 straight quarters of declining SG&A expense from continuing operations, dating back to Q4 2024; for the whole of 2026, we anticipate combined OpEx landing somewhere between $170 million and $175 million. In addition, throughout Q2 we made substantial progress cutting our liabilities tied to the legacy biosimilar business; we anticipate the outstanding obligations will be largely resolved by year-end, at which point they should stop draining cash. To be specific, accrued rebates and reserves, made up mostly of balances connected to divested products, fell from $28.8 million at the close of Q1 to $14.9 million at the close of Q2. Crucially, that decrease resulted chiefly from revised estimates as uncertainties got resolved in our favor, rather than from spending cash. On top of that, TSA payables and accrued liabilities dropped from $61.6 million at the end of the previous quarter to $22.7 million at the end of Q2. As Sameer discussed, LOQTORZI net revenues keep climbing as anticipated; for the full year 2026, we expect LOQTORZI revenue to fall between $57 million and $62 million. Now to the balance sheet. Cash, cash equivalents and investments combined stood at $105.3 million at the close of the second quarter, lower than $167 million at Q1. As I noted before, roughly $39 million of that decline related to TSA obligations, and we anticipate this cash usage will be largely wound down as we move into 2027. We repeat that we believe our funding is adequate through the key data readouts in 2026 and 2027. Q2 kicked off a set of 4 back-to-back quarterly milestone earn-out periods stemming from the UDENYCA divestiture. According to results reported by the buyer, the $37.5 million milestones were not reached in Q2, though they stay eligible for achievement as we enter Q3. Achievement is still contingent on finalizing the buyer's results, including any permitted adjustments under the asset purchase agreement. With that, I'll turn it back to Denny.

Dennis Lanfear executive
#7

Bryan, thanks — and thanks to everyone for being here on our Q2 2026 call. As you've already picked up, this is a thrilling period in which data throughout the pipeline programs are maturing, alongside solid financial performance in sales, costs, and cash. Having reached the 1-year point following the divestitures, we're generating unmistakable organizational momentum. The back half of this year stands out to me in particular, along with the planned public release in October of especially mature data sets; our enthusiasm for the pipeline holds, as does our belief in the chance to move tagmokitug and casdozokitug forward to help cancer patients get past immune resistance.

Paul Jeng analyst
#8

Regarding TAGMO, I found what you said about the initial results from the Series 4 and head and neck cohort quite compelling. As this study moves forward, do you foresee any chance of enrolling subjects prospectively according to HPV status? Also, has orpharyngeal versus non-orpharyngeal been examined as a potential asatciation factor? I have one more question after that.

Dennis Lanfear executive
#9

All right. Wonderful. Paul, I appreciate the question. That one I'll hand over to Dr. Dias.

Rosh Dias executive
#10

Appreciate that, Paul. So yeah, Paul, what we're looking at doing at this point is keeping the accrual going and keeping up the follow-up — and the head and neck cohort matters most here, clearly. We're still waiting on those biomarker data samples to arrive, so my sense is that's really going to shape the way we move forward. And as I said, come October we should be set to share that data in a much more formal way. Good point on oropharyngeal carcinoma — you're right about that. Clearly, that's where a great deal of the HPV-positive disease sits, so that's going to factor into how we examine the data and how we get it out there in the October time frame.

Dennis Lanfear executive
#11

Paul, what do you have next?

Paul Jeng analyst
#12

Sure. My second one concerns Casdozo. Regarding the Phase II trial, you said the results could change as more updates arrive following the upcoming one in the second half. Can you see any timeline for deciding when to move ahead with a Phase III? Would observing a few mature response rates suffice? Or will you hold off until overall survival data from that trial becomes available later on?

Rosh Dias executive
#13

Yes. Thanks once more, Paul. In my view, overall survival will definitely need considerable time to mature. Therefore, I don't see us as having to wait for an overall survival endpoint before moving forward. Again, I believe we'll provide some updates later this year. As the data continues to mature, we expect to be able to say something by the end of this year. After that comes further follow-up regarding scan counts and, once more, the durability issue. But no, I don't foresee any need on our part to wait for a formal overall survival analysis.

Brian Cheng analyst
#14

Perhaps we could begin with LOQTORZI. You've provided guidance of 10% to 15% growth each quarter. I'd like to understand more clearly what's behind the gain in how long patients stay on treatment? Is there a larger movement among individuals who arrive from first-line use, especially following the 6-year JUPITER-02 data announcement? Then I have one brief follow-up.

Dennis Lanfear executive
#15

All right. Sameer, would you like to respond to Brian?

Sameer Goregaoker executive
#16

Alright, and thanks, Brian. So Brian, the momentum we saw this quarter stems from the very same forces at work during earlier periods. Far too many individuals are getting only chemo plus off-label IOs, and we are working to switch those doctors over toward the established substitute — the established favored option, LOQTORZI. Thus, just like in prior quarters, additional doctors came on board with LOQTORZI for an initial time, and additional doctors prescribed LOQTORZI for a later time. Number two, when it comes to how long patients stay on therapy, a steady rise in treatment duration is occurring. That, I expect, will keep being steady given our dual indication, since we also hold the second and third line indication, which carries a rather short treatment duration; therefore we have room to grow both in new patient starts and in duration, which we will keep delivering across upcoming quarters.

Dennis Lanfear executive
#17

Brian, was there something else you wanted to ask?

Brian Cheng analyst
#18

Yeah, and perhaps only a single brief item regarding TAGMO as we approach the head and neck data read later this year. What I'd like to know is whether you could walk us through the timing — when we consider that data read, how might we gain a clearer picture of what TAGMO adds on top of TORI? Are there particular metrics or biomarkers that you believe investors ought to rely on? Also, when the data read happens, will you be in a position to clearly demonstrate that the shifts observed in those biomarkers link to the durability response?

Dennis Lanfear executive
#19

Excellent question. Dr. Lavallee?

Theresa Lavallee executive
#20

Yeah. And clearly, this is extremely timely, what with the discussion that just happened at the advisory committee. We're dealing with a PD-1 refractory population here. So these individuals are progressing — everyone who got enrolled had already progressed while on a prior PD-1 therapy. And we're paying very close attention to how much time passes from progression to the point they enroll in our study. So if someone progressed right away and then signed up, that would mean they aren't responding; so adding TORI together with TAGMO has overcome that resistance. It's also encouraging to see this tied to a metric that includes the target CCR8 positive Tregs. And naturally, we're examining various biomarkers, just as we always do, to demonstrate immune activation, particularly for TAGMO as opposed to TORI by itself. So that's going to be a solid conversation with the FDA, but we have plenty of plans to assess the contribution of effect both rigorously and early, which saves on the number of patients who'd otherwise have to be part of that.

Jay Olson analyst
#21

Congratulations on everything you've accomplished. Given that LOQTORZI keeps showing impressive expansion, with the greatest count of new patient starts since it launched and lengthening treatment duration, could you share your views on how the different LOQTORZI growth drivers might develop over the long haul, such as further penetration in NPC, extended therapy duration, or combination possibilities for LOQTORZI in additional tumor types? And then, if I may, I have a follow-up.

Sameer Goregaoker executive
#22

Jay, thank you for that question. I believe I'll begin by describing what we do not expect to happen anytime soon. At present, we aren't going after a combination in NPC, yet there are ample opportunities inside the NPC indication we currently hold. As I said before, chemotherapy usage in the community setting remains at a fairly elevated level, and we're simply going practice by practice, physician by physician, discussing our 6-year data, which is producing a meaningful effect. During my prepared remarks, I noted that we ran several ad boards and spoke with physicians who had never encountered these data. Once they saw the data, the power of it left them entirely overwhelmed. So properly educating on these data and bringing nonusers into the fold is a key priority at this moment. The second priority, which I mentioned earlier, involves therapy duration, which also matters, since 2 factors exist within duration of therapy. One is getting additional earlier line patients onto therapy. And for first-time users, we also observe some inappropriate dosing along with discontinuations. Thus our emphasis is on teaching those physicians to essentially halt that. Those, then, would be my priority drivers for LOQTORZI.

Dennis Lanfear executive
#23

Sameer, could you add a bit more color regarding the scope and intensity of adoption we're witnessing?

Sameer Goregaoker executive
#24

Absolutely. The extent to which adoption is spreading really matters, since our share of the market keeps climbing, and over 50% of the physicians we can reach have never prescribed LOQTORZI. That's entirely an awareness problem. They don't encounter many NPC patients. And on the occasions they do see an NPC patient, LOQTORZI isn't the first thing that comes to mind. So we're expanding that breadth — each quarter, we bring in a fairly large number of new accounts and new physicians prescribing LOQTORZI. So breadth is a genuinely important piece. Then there's depth, correct? Because whenever we convert a physician to LOQTORZI, we want to be certain they keep prescribing LOQTORZI for each and every patient afterward. And we're making solid headway on that front. We're observing fairly strong depth and repeat prescribing of LOQTORZI among the new physicians currently prescribing LOQTORZI.

Jay Olson analyst
#25

Excellent. If I may, I'd like to slip in one more question regarding TAGMO. Given the information you've gathered up to this point, when we think about the data you'll be sharing in October, what should investors be paying closest attention to — in particular, are there any measures other than ORR that you believe deserve special notice?

Dennis Lanfear executive
#26

<<inaudible>> Rosh.

Rosh Dias executive
#27

Absolutely, Jay, and thank you for raising that. What we've consistently emphasized is the importance of examining the full body of evidence, and that's precisely where our attention will be directed. So when we get to the October readout, the things we'll be evaluating include, as you pointed out, not just the overall response rate but also — and this matters greatly — the clinical benefit rate. That encompasses the response rate for stable disease, how long that stable disease lasts, and the durability of responses too. Along with safety and tolerability, naturally, those will serve as highly meaningful measures. We've already discussed the EGFRs and certain toxicities associated with them. So this strikes me as another key consideration, and beyond that, we'll be applying those very same metrics across the various biomarker analyses.

Nick Quartapella analyst
#28

This is Nick sitting in for Colleen. We just had a session on the Casdozo program, so with triplet data coming soon in HCC, I was hoping you could discuss which metrics you anticipate presenting there. And then more specifically, what findings do you believe would be required for you to feel greater confidence about the triplet in this indication? And in particular, is there anything else we ought to be watching, given that ORR probably won't be as elevated as it will be once the data are more mature?

Rosh Dias executive
#29

Yes. I appreciate the question. So once more, like I said before, what we'll examine is the data in its entirety, correct? So indeed, response rate, we'll be examining how long the CBR lasts, and so on and so forth, all the things I brought up previously. Beyond that, we're likewise examining ctDNA to help inform how we consider the possibility of durable response and survival. And after that we'll also examine baseline IL-27 levels too, to determine whether we — how those might relate to what we're observing; we highlighted this before. And something to keep in mind is that this data in HCC specifically does require a certain amount of time to mature. Looking at the earlier study, there was a period needed to establish a baseline, followed by a rise in response rate at baseline, and then the response deepened; so that's roughly what we expect in this case too, though we'll be examining all those various metrics I referred to at the start.

Douglas Tsao analyst
#30

Douglas, you asked about my remark on needing to fix dosing with certain clinicians. I wanted to know if you could share more specifics on what we're observing or what's going on in that area?

Sameer Goregaoker executive
#31

Yes. I'll briefly address that. During this quarter we completed some preliminary analysis and identified a few opportunities. There are 2 indications for us. The frontline indication uses Q3 weekly dosing, while our late-line indication uses Q2 weekly dosing. We suspected that a number of physicians may not be dosing according to the indication, giving a Q 3-week schedule when it ought to be Q2-week. That gives us something to address. Beyond that, our indication calls for treating to progression rather than for 6 cycles. That's one more place where we could potentially set things right and encourage proper dosing of the drug. Once again, I want to emphasize that this is a secondary opportunity. Getting those who aren't using LOQTORZI to start using LOQTORZI remains our largest opportunity, though we'll also be pushing for correct dosing among our current physicians.

Douglas Tsao analyst
#32

And Sameer, what I mean is, I realize this isn't really the main priority. Still, I'm wondering how significant it is, or whether you could give us a rough idea of how big the issue might be — that you're perhaps — how much revenue, roughly, is going unclaimed as a result of some of what's happening?

Sameer Goregaoker executive
#33

What I'd say is that the upside on duration represents a substantial opportunity for us. Putting a figure on it isn't possible at this moment, since everything rests on claims data, and we're only now examining it more closely. So allow us a bit of time to look into it further. That said, I can tell you we have observed certain indications that an opportunity exists there.

Douglas Tsao analyst
#34

Sameer, one more question if I may, building on what we just discussed. Have you actually spoken with physicians and gotten the chance to really probe them about what could be going on? Is this simply confusion around the dosing? Or do they hold a somewhat different view regarding how they'd like to use the drug?

Sameer Goregaoker executive
#35

My view is that this is nothing more than confusion about dosing. Keep in mind, as I said before, they treat NPC perhaps only one time per year; and whenever a case appears, unless we get in front of them prior to starting therapy and instruct them precisely on the method, misdosing can happen, correct? So this is mainly a matter of education, which is what we're working to fix.

Dennis Lanfear executive
#36

Appreciate that, Heidi. And thanks to everyone for being here on our Q2 2026 call. It's a pleasure to bring you the latest on our clinical development program and the solid sales momentum we've built. I'd like to express my gratitude to Sameer for that 15% gain. As a reminder, we'll be taking part in several investment conferences in New York, along with Byrons in September, and we're eager to share our clinical progress with you in October. Thank you.

Operator operator
#37

Goodbye; this concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Coherus Oncology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Coherus Oncology, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.